<DOC>
	<DOCNO>NCT01491594</DOCNO>
	<brief_summary>The purpose study study effect eltrombopag chemotherapy induce thrombocytopenia . Thrombocytopenia low number platelet blood . Sometimes , thrombocytopenia occurs side effect chemotherapy treatment .</brief_summary>
	<brief_title>Eltrombopag Prevention Chemotherapy Induced Thrombocytopenia</brief_title>
	<detailed_description>The combination chemotherapy regimen gemcitabine docetaxel become increasingly used treatment choice subject advance sarcoma . The regimen show activity first second line subject metastatic uterine leiomyosarcoma , relapsed/refractory pediatric sarcoma , improve progression-free survival overall survival person metastatic sarcoma compare gemcitabine alone . The regimen additionally recognize treatment option subject advance sarcoma . Chemotherapy-induced toxicity blood low platelet level common often therapy-limiting side effect treatment . There two phase study . The purpose Phase I study determine recommend dose eltrombopag . The purpose Phase II study determine safety , tolerability , efficacy ( well drug work ) eltrombopag subject receive gemcitabine docetaxel chemotherapy . Eltrombopag ( Promacta ) FDA approve drug treatment chronic idiopathic thrombocytopenic purpura ( ITP ) - condition abnormally low platelet count . Eltrombopag investigate thrombocytopenic ( low platelet ) disorder . Participants take assign dose eltrombopag day start five day cycle chemotherapy 5 day chemotherapy . Eltrombopag take day chemotherapy . Eltrombopag take orally .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Neoplasms , Connective Soft Tissue</mesh_term>
	<criteria>Metastatic soft tissue bone sarcoma 18 year age old Adequate blood count Adequate kidney liver function At least 1 3 prior systemic therapy regimens cancer Good performance status able carry work light sedentary nature Preexisting hear disease congestive heart failure , arrhythmia know increase risk thromboembolic event ( blood clot ) Blood clot last 6 month , know clot problem platelet disorder History brain cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Metastatic sarcoma</keyword>
	<keyword>Bone sarcoma</keyword>
</DOC>